Vensica Medical is developing a needle-free, painless procedure for the delivery of Botox® to treat overactive bladder.

The Vensica Opportunity

The market seeks a safe, painless method to deliver Botox into the bladder wall, without needles.

The Product & Advantages

Vensica is developing an ultrasound catheter used to deliver Botox into the bladder wall painlessly and without the use of needles. The catheter leverages the known properties of ultrasound (opens pores in the tissue and “pushes” the drug through these pores). The procedure using Vensica’s system can be performed in the doctor’s office or clinic, without anesthesia. Read more about the idea behind Vensica’s system.

  • Simplifies treatment: Direct visualization of the bladder wall is not required.
  • Reduces costs: The simple procedure can be performed in an office or clinic, not the operating room.
  • Improves patient satisfaction: Painless procedure, no sedation required.
  • Reduces risk: Needle-free procedure eliminates potential infections associated with injections.

The Team


Vensica Medical CEO Avner Geva

  • Avner Geva, CEO: Extensive experience in the medical device field; biomedical engineering, Technion-Israel Institute of Technology; premedical studies and molecular biology, Yale University
  • Leonid Kushkuley, Ultrasound Engineer: More than 30 years of therapeutic ultrasound development experience
  • Prof. Roger Dmochowski, Advisory Board: Chairman, Department of Urology, Vanderbilt Medical Center, Nashville, Tennessee
  • Prof. Alan Wein, Advisory Board: Chairman, Department of Urology, Hospital of the University of Pennsylvania

Trendlines’ directors: Todd Dollinger, Steve Rhodes


Founded: August 2014
Stage: Business development; signed term sheet for new investment by undisclosed strategic investor
Investor: The Trendlines Group
IP: Filed PCT application


  • Cogentix Medical invests $2 million, part of structured acquisition
  • Successful preclinical trials

In the Media

Background & Market

Overactive bladder (OAB), characterized by the urgent need to urinate and involuntary loss of urine, has a negative impact on the quality of life. In 50% of the cases, medications are ineffective and often have significant side effects. In 2011, the FDA approved the use of Botox to treat OAB. This procedure is performed using a cystoscope (to visualize the interior of the bladder) and a needle to inject the Botox. While Botox has demonstrated effectiveness in treating OAB, the procedure is expensive, painful (20-30 injection sites), risky (urinary tract infections), and in most cases performed under sedation.

OAB is the most common type of bladder disorder. There are an estimated 39 million people in the United States alone with OAB, and 4 million of them are unsatisfied with treatment.*

*W. Stuart Reynolds , Jay Fowke, Roger Dmochowski. The Burden of Overactive Bladder on US Public Health. Curr Bladder Dysfunct Rep. 2016 March. The Total Economic Burden of Overactive Bladder in the United States: A Disease Specific Approach.  2009 March.


Watch CEO Avner Geva's interview on Israel Daily TV.

See Avner Geva's presentation at Trendlines 6th Annual Company Showcase.

Vensica Medical's Vensicare system
Vensica's needle-free, painless procedure deliver Botox to the bladder wall to treat overactive bladder.


Avner Geva, CEO

Vensica logo

Font Resize